PMID- 36199496
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221007
IS  - 2150-0878 (Print)
IS  - 2150-0886 (Electronic)
IS  - 2150-0878 (Linking)
VI  - 13
IP  - 7
DP  - 2022 Sep
TI  - Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal 
      Melanoma.
PG  - 717-723
LID - 10.6004/jadpro.2022.13.7.8 [doi]
AB  - Uveal melanoma is the most common intraocular cancer in adults. Metastatic uveal 
      melanoma has a poor prognosis. Tebentafusp-tebn is the first drug in the new 
      immune mobilizing monoclonal T-cell receptors against cancer (ImmTAC) class of T 
      cell-directed therapy. Tebentafusp-tebn has been shown in a randomized phase III 
      clinical trial to lead to improved overall survival and progression-free survival 
      when compared with single-agent pembrolizumab, ipilimumab, or dacarbazine in 
      previously untreated human leukocyte antigen (HLA)-A*02:01-positive metastatic 
      uveal melanoma patients. Tebentafusp-tebn is now approved by the US Food and Drug 
      Administration in HLA-A*02:01-positive uveal melanoma patients as first-line 
      therapy in the metastatic setting.
CI  - (c) 2022 Harborside.
FAU - Hua, Gwen
AU  - Hua G
AD  - Geisinger Enterprise Pharmacy, Danville, Pennsylvania.
FAU - Carlson, Daniel
AU  - Carlson D
AD  - Geisinger Cancer Institute, Danville, Pennsylvania.
FAU - Starr, Jacqueline R
AU  - Starr JR
AD  - Geisinger Enterprise Pharmacy, Danville, Pennsylvania.
LA  - eng
PT  - Journal Article
DEP - 20221012
PL  - United States
TA  - J Adv Pract Oncol
JT  - Journal of the advanced practitioner in oncology
JID - 101550346
PMC - PMC9514125
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2022/10/07 06:00
MHDA- 2022/10/07 06:01
PMCR- 2022/09/01
CRDT- 2022/10/06 02:07
PHST- 2022/10/06 02:07 [entrez]
PHST- 2022/10/07 06:00 [pubmed]
PHST- 2022/10/07 06:01 [medline]
PHST- 2022/09/01 00:00 [pmc-release]
AID - 2022.13.7.8 [pii]
AID - 10.6004/jadpro.2022.13.7.8 [doi]
PST - ppublish
SO  - J Adv Pract Oncol. 2022 Sep;13(7):717-723. doi: 10.6004/jadpro.2022.13.7.8. Epub 
      2022 Oct 12.